Top Page
TELA Bio
(NASDAQ:TELA)
TELA Bio (TELA) vs. SPDR S&P 500 ETF (SPY)
TELA Bio Business Overview & Revenue Model
TELA Bio Earnings Call Summary
TELA Bio Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 75.32M | 69.30M | 58.45M | 41.42M | 29.46M | 18.21M |
| Gross Profit | 50.70M | 46.49M | 40.11M | 27.04M | 18.81M | 11.23M |
| EBITDA | -34.73M | -31.68M | -40.63M | -39.06M | -29.14M | -24.70M |
| Net Income | -40.77M | -37.84M | -46.66M | -44.30M | -33.28M | -28.79M |
Balance Sheet | ||||||
| Total Assets | 67.54M | 86.57M | 78.05M | 67.86M | 62.54M | 86.46M |
| Cash, Cash Equivalents and Short-Term Investments | 34.98M | 52.67M | 46.73M | 42.02M | 43.93M | 74.39M |
| Total Debt | 41.90M | 41.67M | 41.08M | 40.26M | 31.49M | 30.83M |
| Total Liabilities | 58.35M | 58.11M | 59.17M | 53.55M | 42.45M | 37.43M |
| Stockholders Equity | 9.18M | 28.46M | 18.88M | 14.30M | 20.10M | 49.03M |
Cash Flow | ||||||
| Free Cash Flow | -34.68M | -42.58M | -41.47M | -42.62M | -31.06M | -24.62M |
| Operating Cash Flow | -34.14M | -41.59M | -40.86M | -40.75M | -30.43M | -24.46M |
| Investing Cash Flow | 30.00K | 4.45M | -599.00K | -1.87M | -627.00K | 9.12M |
| Financing Cash Flow | 42.89M | 43.06M | 46.27M | 40.85M | 585.00K | 44.41M |
TELA Bio Technical Analysis
TELA Bio Risk Analysis
TELA Bio Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | $70.96M | ― | -5.71% | ― | -13.79% | -132.21% | |
53 Neutral | $36.14M | -4.57 | -95.39% | ― | 145.48% | 67.36% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $70.08M | -1.20 | -73.73% | ― | 15.59% | 4.13% | |
40 Underperform | $48.96M | -2.58 | -230.80% | ― | -16.46% | 4.14% | |
39 Underperform | $51.11M | -1.15 | ― | ― | 12.24% | 47.45% | |
38 Underperform | $49.66M | -4.34 | -96.15% | ― | -8.97% | 47.29% |
TELA Bio Corporate Events
On November 13, 2025, TELA Bio, Inc. entered into a Credit Agreement with Perceptive Credit Holdings V, LP, for a senior secured term loan facility of up to $70 million, with an initial $60 million loan funded on November 14, 2025. This agreement, which includes warrants for common stock, aims to enhance the company’s financial flexibility and support its operational growth. Additionally, TELA Bio announced a registered direct offering of common stock and pre-funded warrants, expected to close on November 17, 2025, with net proceeds of approximately $11.9 million intended for general corporate purposes. This financial maneuvering is likely to impact the company’s market positioning by providing necessary capital for expansion and operational needs.
The most recent analyst rating on (TELA) stock is a Hold with a $1.25 price target. To see the full list of analyst forecasts on TELA Bio stock, see the TELA Stock Forecast page.
TELA Bio, Inc. is a commercial-stage medical technology company specializing in innovative soft-tissue reconstruction solutions, aiming to optimize clinical outcomes by leveraging the patient’s natural healing response while minimizing exposure to synthetic materials.
On November 13, 2025, TELA Bio reported its third-quarter financial results, highlighting a 9% revenue increase to $20.7 million compared to the same period in 2024. The company also announced a strengthened capital position through a $70 million credit facility with Perceptive Advisors, expanded its board, and accelerated hiring in its U.S. sales organization. Despite a net loss of $8.6 million, the results reflect strategic changes and leadership enhancements that are expected to support future growth. TELA Bio revised its full-year 2025 revenue guidance to at least 16% growth over 2024, demonstrating confidence in its operational strategies and market positioning.
The most recent analyst rating on (TELA) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on TELA Bio stock, see the TELA Stock Forecast page.
On October 31, 2025, TELA Bio, Inc. expanded its Board of Directors from six to seven members by appointing William Plovanic as a Class I director, with his term set to expire at the 2026 Annual Meeting of Stockholders. Mr. Plovanic, with extensive experience in healthcare equity research and leadership roles in medical technology companies, is expected to bring valuable insights to TELA Bio. His appointment, accompanied by an initial equity award, aligns with the company’s non-employee director compensation policy, potentially enhancing TELA Bio’s strategic direction and governance.
The most recent analyst rating on (TELA) stock is a Sell with a $1.00 price target. To see the full list of analyst forecasts on TELA Bio stock, see the TELA Stock Forecast page.
Study Overview: Tela Bio, Inc. is conducting a study titled Research on the Effectiveness and Safety of Treatment With OviTex® PRS – a Breast Reconstruction Evaluation. The primary goal of this study is to assess the safety and effectiveness of the OviTex PRS device in patients undergoing implant-based breast reconstruction. This research is significant as it aims to provide insights into a potentially improved method for breast reconstruction, which could enhance patient outcomes and satisfaction.
Study Overview: Tela Bio, Inc. is conducting a clinical study titled A Prospective Study Evaluating the Clinical Outcomes of Ventral or Inguinal Hernias Treated Robotically With OviTex® Reinforced Tissue Matrix. The study aims to assess post-operative complications and hernia recurrence in patients treated with OviTex, involving up to 160 participants across 20 sites. This research is significant as it seeks to improve surgical outcomes for hernia patients.
Study Overview: Tela Bio, Inc. is conducting a study titled A Prospective Study Evaluating Clinical Hiatal Hernia Outcomes Using OviTex® Reinforced Tissue Matrix. The study aims to assess the recurrence rate of hiatal hernias and post-operative complications when using OviTex Core Resorbable or OviTex 1S Resorbable. This research is significant as it seeks to improve surgical outcomes for patients with hiatal hernias, a common condition that can lead to severe complications if not effectively managed.
Study Overview: Tela Bio, Inc. is conducting a study titled ‘A Retrospective Assessment of OviTex PRS (OviTex) Permanent and Resorbable Devices in Subjects Who Have Previously Undergone a Breast Reconstruction.’ The study aims to evaluate the safety profile of OviTex PRS devices used in breast reconstruction surgeries, focusing on both permanent and resorbable device types. This research is significant as it seeks to provide insights into the safety and effectiveness of these devices, potentially influencing surgical practices and patient outcomes.
On October 4, 2025, TELA Bio, Inc. announced the resignation of Lisa Colleran from its Board of Directors, where she also served on the Nominating and Corporate Governance Committee and the Audit Committee. Her resignation was not due to any disagreements with the company’s operations or policies. Subsequently, on October 7, 2025, the company appointed Dr. Betty Jo Rocchio to the Board, effective October 9, 2025. Dr. Rocchio, who has an extensive background in nursing leadership, will serve as a Class I director until the 2026 Annual Meeting of Stockholders. Her appointment is aligned with TELA Bio’s non-employee director compensation policy, which includes an initial equity award and an annual base retainer.
The most recent analyst rating on (TELA) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on TELA Bio stock, see the TELA Stock Forecast page.
In the recent earnings call, TELA Bio, Inc. showcased a positive sentiment overall, driven by significant revenue growth in its OviTex and LIQUIFIX portfolios and successful expansion in the European market. Despite facing challenges such as net loss and a slight increase in sales and marketing expenses, the company’s achievements in revenue and market expansion were prominent highlights.